Dr. Christopher M. Pace, MD

Dr. Pace practices at Icare Health Surgical Suites LLC in Bedford, Texas.

Dr. Pace's NPI, 1912993080, was assigned on September 23, 2005. Dr. Pace graduated from Jacobs School of Medicine and Biomedical Sciences in 1996. Dr. Pace holds Texas license K4762.

Dr. Pace's primary practice is Icare Health Surgical Suites LLC, at 1604 Hospital Pkwy, Bedford, TX 76022 in Tarrant County. The practice phone is (682) 688-2020.

Dr. Pace's primary practice is Icare Health Surgical Suites LLC in Bedford, Texas. Dr. Pace is also affiliated with Texas Health Harris Methodist Hospital Hurst-Euless-Bedford. The medical group on file is Urology Partners of North Texas. Dmand AI also links Dr. Pace to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pace practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Pace's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Pace is board certified in urology by the American Board of Urology. Dr. Pace is licensed in Texas.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate inflammation or infection among the conditions Dr. Pace treats.

CMS data shows 3,005 Medicare services from Dr. Pace across 32 procedure codes in 2024, for 534 Medicare patients. Medicare paid $107,553 for them.

CMS counts 534 Medicare patients who saw Dr. Pace in 2024. The largest group is 75 to 84, with 220 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pace's median patient age at 70, with 29% women.

In 2024, Dr. Pace wrote 2,438 Medicare Part D claims for 532 patients. 92% of them were for generic drugs. CMS names the drug for 2,305 of them, across 28 drugs with 11 or more claims each, at $350,568 in total drug cost. In 2023, CMS named 2,018 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Pace for performance year 2024, reported as part of a group. Dr. Pace accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pace as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Pace. Dr. Pace's most frequent co-authors are Elie Benaim, MD and Claus G. Roehrborn, MD.

CMS Open Payments shows 221 general payments to Dr. Pace from 44 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Astellas Pharma US Inc paid the most, $614.

Dmand AI lists 1 award for Dr. Pace, most recently CMS Stage 1 2012 in 2012.

Dr. Pace graduated from Jacobs School of Medicine and Biomedical Sciences in 1996.

Dr. Pace is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.